Childhood Exposure to Second Hand Smoke Increases Lung Cancer Risk for Adults According to New Study

MAYWOOD, NJ -- Feb. 2, 2005 -- A new study published in the online edition of the British Medical Journal has found evidence that childhood exposure to second hand smoke increases the risk of acquiring lung cancer as an adult (BMJ, (Jan 28 2005) doi:10.1136/bmj.38327.648472.82). The researchers conducted a seven year follow-up of 60,182 non-smokers as part of a large ongoing European study. They found that adults reporting exposure to second hand smoke in childhood were more at risk for lung cancer as compared to unexposed adults. Adults who reported daily childhood second hand smoke had twice the risk of lung cancer; those reporting heavy daily exposure had over three and a half times the risk.

TobacAlert(TM) is Nymox’s revolutionary new product that allows concerned individuals to determine second hand smoke exposure by measuring the level of cotinine, a metabolite of nicotine, in urine. TobacAlert(TM) is a quick, accurate and easy to use test that can be done almost anywhere, including at home, the workplace or school and that requires no instruments to use. More information about TobacAlert(TM) is available at www.tobacalert.com.

“I do not believe people understand how much their smoking might be affecting their loved ones. Those parents who claim to not smoke in front of their children are sometimes in for a big surprise when they see the results from the test,” said Brian Doyle, Nymox’s Global Sales Manager.

TobacAlert(TM) is available at a retail price of $14.99 at CVS, America’s number one retail pharmacy, with approximately 5,400 stores, as well as online at www.cvs.com.

TobacAlert(TM) uses patented technology to provide a semi-quantitative measure of cotinine, a byproduct of the body’s metabolism of nicotine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product exposure. TobacAlert(TM) is intended only to assess an individual’s level of tobacco product exposure and not for any medical treatment purposes.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

Vincent Daniels

VP - Investor Relations

Porter, Le Vay & Rose, Inc.

Contact via E-mail